ThermoGenesis to Join Russell Microcap® Index

Rhea-AI Summary

ThermoGenesis Holdings, Inc. (Nasdaq: THMO) will join the Russell Microcap Index following the annual reconstitution, effective June 29, 2020. This inclusion signifies the company’s improved financial and operational performance over the past year. The Russell Microcap Index is key for institutional investors, with approximately $9 trillion in assets benchmarked against it. CEO Chris Xu emphasized that this milestone will enhance visibility within the investment community as ThermoGenesis aims to lead in automated technologies for cell and gene therapy.

Positive

• Inclusion in the Russell Microcap Index enhances visibility to investors.
• Reflects improvement in financial and operational performance.

Negative

• None.

RANCHO CORDOVA, Calif., June 16, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that the Company is set to join the Russell Microcap® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market opens on June 29, according to a final list of additions posted June 15.

Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

"Inclusion in the Russell Microcap Index demonstrates the continued improvement of our financial and operational performance over the last year," said Chris Xu, PhD, Chief Executive Officer of ThermoGenesis. "We anticipate that our addition to the index will increase our visibility to the investment community as we continue to execute our strategy to become a leading provider of automated technologies for the cell and gene therapy field and as we leverage our global resources in the fight against the COVID-19 global pandemic."

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell 3000^® Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.

About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: -1%26h%3D278871176%26u%3Dhttp%253A%252F%252Fwww.thermogenesis.com%252F%26a%3Dwww.thermogenesis.com&a=www.thermogenesis.com" rel="nofollow">www.thermogenesis.com.

Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect the current expectations of ThermoGenesis concerning future events and results. Forward-looking statements based on ThermoGenesis' current assumptions, expectations and beliefs are generally identifiable by use of words "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue," or similar expressions and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. Such forward-looking statements involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, market and other conditions, as well as those risk factors discussed in Item 1A of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") as well as other documents that may be filed by ThermoGenesis from time to time with the SEC, which are available at -1%26h%3D3037386902%26u%3Dhttp%253A%252F%252Fwww.sec.gov%252F%26a%3Dwww.sec.gov&a=www.sec.gov" rel="nofollow">www.sec.gov. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Company Contact:
Wendy Samford
916-858-5191
ir@thermogenesis.com

Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com

 

View original content:http://www.prnewswire.com/news-releases/thermogenesis-to-join-russell-microcap-index-301077500.html

SOURCE ThermoGenesis Holdings, Inc.

FAQ

When will ThermoGenesis join the Russell Microcap Index?

ThermoGenesis will join the Russell Microcap Index on June 29, 2020.

What does joining the Russell Microcap Index mean for THMO?

Joining the Russell Microcap Index can increase visibility to institutional investors and improve access to capital.

How much in assets are benchmarked against Russell indexes?

Approximately $9 trillion in assets are benchmarked against Russell's US indexes.

Why is ThermoGenesis's inclusion in the Russell Microcap Index significant?

It indicates the company's improved financial and operational performance, enhancing investor interest.